DJIA 18,132.70 -81.72 -0.45%
NASDAQ 4,963.53 -24.36 -0.49%
S&P 500 2,104.50 -6.24 -0.30%
market minute promo

5.64 -0.23 (-3.92%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

OREX $5.64 -3.92%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.86
Previous Close $5.87
Daily Range $5.60 - $5.86
52-Week Range $3.11 - $7.82
Market Cap $694.7M
P/E Ratio -18.34
Dividend (Yield) $0.00 (0.0%)
Volume 1,802,447
Average Daily Volume 1,950,776
Current FY EPS -$0.45




Drug Makers

Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website:

News & Commentary Rss Feed

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch

Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.

Orexigen's Q4 Results Disappoint, But Contrave Is Gaining Market Share

Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog

Why Vivus Inc Plummeted Today

Vivus Inc shares tanked today following results that failed to impress.

Orexigen's (OREX) CEO Mike Narachi on Q4 2014 Results - Earnings Call Transcript

UPDATE: Orexigen Therapeutics Shares Drop After Q4 Results

Health Care Sector Update for 02/25/2015: ARGS, OREX, AMPE

Orexigen Therapeutics (OREX) Q4 2014 Results - Earnings Call Webcast

Arena: Belviq Television Ads Resume After 1 Week Hiatus

Orexigen's Contrave Scaling New Heights

See More OREX News...

OREX's Top Competitors

OREX $5.64 (-3.92%)
Current stock: OREX
AMGN $157.72 (-0.79%)
Current stock: AMGN
GILD $103.53 (-0.63%)
Current stock: GILD
BIIB $409.59 (-0.12%)
Current stock: BIIB